|
|
Vaccine Detail
|
Brachyury-expressing Modified Vaccinia Ankara-TRICOM Vaccine |
| Vaccine Information |
- Vaccine Name: Brachyury-expressing Modified Vaccinia Ankara-TRICOM Vaccine
- Target Pathogen: Cancer
- Target Disease: Cancer
- Vaccine Ontology ID: VO_0007331
- Type: Other
- Status: Clinical trial
- Host Species for Licensed Use: Human
- Host Species as Laboratory Animal Model: Human
- CD8A
gene engineering:
- Type: Recombinant protein preparation
- Description:
- Detailed Gene Information: Click Here.
- Preparation: rV-B7-1/ICAM-1/LFA-3 (designated rV-TRICOM) is a recombinant vaccinia virus that contains the murine LFA-3 gene under control of the vaccinia 30k (M2L) promoter (18) , the murine ICAM-1 gene under control of the vaccinia I3 promoter (19) , and the murine B7-1 gene under control of the synthetic early/late (sE/L) promoter (Hodge et al., 1999; Fernando et al., 2010)
- Description: A cancer vaccine composed of a replication-deficient, attenuated derivative of the vaccinia virus strain Ankara expressing both a CD8+ T-cell epitope from the brachyury protein and a triad of T-cell co-stimulatory molecules (MVA Brachyury-TRICOM), with potential immunomodulating and antineoplastic activities. Upon subcutaneous administration of the brachyury-expressing modified vaccinia Ankara (MVA)-TRICOM vaccine, the expressed brachyury protein induces specific CD8+ and CD4+ T-cell responses against brachyury-expressing tumor cells. This causes both tumor cell lysis and a decrease in the growth of brachyury-expressing tumor cells. Brachyury, a member of the T-box family of transcription factors that is overexpressed in numerous cancer cell types, is correlated with increased epithelial-mesenchymal transition (EMT), cancer resistance and cancer progression. TRICOM, a triad of three human T-cell co-stimulatory molecules, B7.1, ICAM-1 and LFA-3, enhances antigen-specific T-cell activation. (NCIT_C116777). This vaccine has been used in clinical trials involving prostate cancer. https://www.cancer.gov/about-cancer/treatment/clinical-trials/search/v?id=NCI-2022-05711&r=1
|
| Host Response |
|
|
| References |
Fernando et al., 2010: Fernando RI, Litzinger M, Trono P, Hamilton DH, Schlom J, Palena C. The T-box transcription factor Brachyury promotes epithelial-mesenchymal transition in human tumor cells. The Journal of clinical investigation. 2010; 120(2); 533-544. [PubMed: 20071775].
Hodge et al., 1999: Hodge JW, Sabzevari H, Yafal AG, Gritz L, Lorenz MG, Schlom J. A triad of costimulatory molecules synergize to amplify T-cell activation. Cancer research. 1999; 59(22); 5800-5807. [PubMed: 10582702].
NCIT_C116777: [https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C116777]
|
|
